Advancing Cell & Gene Therapy in East AsiaThe East Asia region is making great progress in developing cell and gene therapy to address and bring hope to the high unmet medical needs. As part of the new wave of advanced therapy medicinal product (ATMP), cell and gene therapy biopharmas in the East Asia region has contributed extensive capital investment in research & development of novel therapeutic agents, setting state-of-art manufacturing plants while collaborations are formed between multinational companies to accelerate the progress and developments of cell and gene therapy industry. Growing at a compound growth rate of above 14%, the cell and gene therapy market in East Asia is expected to reach USD 2.9 billion by 2028. Among the countries, China, Korea, Japan and Taiwan showed exceptional achievements in R&D of cell & gene therapy products and offered great potential for treatment of various diseases.
In this edition of Cell and Gene Therapy World East Asia, key opinion leaders from major key players in the East Asia region industry come together to discuss carefully researched content to address the challenges and explore opportunities of CAR-T/NK products manufacturing, technologies to develop cell and gene therapy products, best practices of clinical trials, case studies and more. This is the one and only Cell and Gene Therapy conference to help explore collaboration and partnership opportunities in the East Asia region to address life-saving medicine.
#imapac #cellandgene, #ccpeventcalendar, #pharma, #ClinicalTrialLogistics, #KoreanColdChain, #2023events